Patient and prescriber survey: effectiveness measures to investigate awareness, knowledge, and adherence to the additional risk minimisation measures (aRMM) of the patient reminder card for oral ambrisentan (PrVolibris®)

drug protocol number
221772
drug sponsor
GSK
drug study
Ambrisentan
drug trial site
King Abdullah International Medical Research Center– Jeddah
drug status
Ongoing
drug phase